![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Acetaminophen reduces COX pathway activity and is thought to inhibit the synthesis of prostaglandins in the central nervous system, leading to its analgesic and antipyretic effects.
Lead Product(s): Paracetamol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
The first OTC pain relievers containing acetaminophen without artificial dyes, fillers, and preservatives to launch at Walmart and other national retailers,rovides temporary relief of occasional headaches and minor aches and pains with accompanying sleeplessness.
Lead Product(s): Paracetamol
Therapeutic Area: Neurology Product Name: Acetaminophen-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022